# Pizarra — PT-pseudo_075dd468b384 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_075dd468b384
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 13.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.14 ng/mL²
  - PSA velocity: 2.7 ng/mL/yr
  - Prior PSA: 10.2 ng/mL
  - Prostate volume: 96.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6351894 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia
  - Current medication: amlodipine, atorvastatin, simvastatin
  - Allergies: NSAIDs
  - Additional notes: PSA 13.2 ng/mL. PI-RADS 4. PSAD 0.14. Prostate volume 96 mL. DRE nodus. csPCa 0.64.

Vitals: weight 60 kg, height 178 cm, BMI 18.9, BP 146/82 mmHg, HR 70 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2010).

Chief complaint: Specialist reassessment sought due to a steadily rising PSA curve alongside historical biopsy results.

History: A 66-year-old office administrator arrives for specialist review after an initial PSA elevation in 2022. Married and settled in an independent unit of a retirement community, he walks 45 minutes daily and avoids alcohol entirely. His medical background encompasses hypertension and hypercholesterolaemia, treated with amlodipine, atorvastatin, and simvastatin. A substantial smoking history of 33 pack-years was concluded in 2010. Lower urinary tract complaints remain mild, scoring 5 out of 35 on the IPSS. Documented hypersensitivity to NSAIDs exists, necessitating large-print correspondence, and his brother serves as his designated next of kin. Unrelated to the current urological focus, he had uncomplicated cataract extraction in 2018, recently visited a sleep clinic for suspected obstructive sleep apnoea, and maintains routine podiatry appointments for foot care.

Physical examination: DRE — texture: firm; asymmetry: present; location: left posterior peripheral zone (Nodus). The remainder of the abdominal and cardiovascular assessment proves unremarkable, recording a blood pressure of 146/82 mmHg and a heart rate of 70 bpm. General inspection reveals a slender physique with a BMI of 18.9, alongside adequate nutritional status and an absence of acute distress.

Patient info: office administrator; Married; Lives in retirement community (independent unit).
Next of kin: Sibling (brother).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Sleep clinic — suspected obstructive sleep apnoea; Podiatry — routine foot care.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.17   (95% CI 0.07-0.75)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.17  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.98 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size and zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 13.2 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement regarding the prior positive biopsy?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with the current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the initial panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the rising PSA velocity (2.7 ng/mL/yr) and the specific PI-RADS 4 score, which are critical dynamic factors not fully captured by static variables like prior biopsy status or baseline PSA.
The prior did not weigh the specific PSA density (0.14 ng/mL²) or the DRE finding (Nodus), which are key components in risk stratification matrices referenced in the guidelines.
The prior did not account for the specific guideline criterion that the decision hinges on the retrieved documents (MRI, PSA trend, prior notes) because it only processed the initial structured panel.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.41 +/- 0.17, placing it in the 'discuss' tier. This suggests the model cannot distinguish between biopsy and deferral based on the input. Given the rising PSA (10.2 to 13.2 ng/mL) and PI-RADS 4, a low probability for biopsy might be dangerously conservative, especially if the underlying data distribution is skewed towards higher risk in this specific subgroup. The high aleatoric uncertainty (H=0.98) indicates the model is highly uncertain about the correct classification for this specific patient profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size and zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value of 13.2 ng/mL?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement regarding the prior positive biopsy?
4. laboratory panel - (Dropped by Moderator, but if retrieved, it might provide context on other markers).

GUIDELINE ANCHOR
The guideline search indicates that the decision is heavily dependent on the MRI findings and the prior biopsy status, noting that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15ng/mL/cc.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC – Radiology Division
Date: 10 Jan 2025 | Modality: Multiparametric MRI Prostate

Imaging Details: The gland demonstrates marked hypertrophy, totaling 96.0 mL in overall volume. Within the left mid-gland peripheral zone, a 12 x 8 mm focus exhibits restricted diffusion on DWI/ADC alongside early enhancement on DCE sequences.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 4 lesion in the left mid-gland peripheral zone with restricted diffusion and early enhancement.
- PSA trend: Serial PSA rise from 10.2 ng/mL (Mar 2024) to 13.2 ng/mL (Jan 2025), indicating a rising trajectory.

AGAINST Sampling this patient now:
- Previous notes: Prior biopsy result is documented as 'Positive', which is a known diagnosis.

WHERE THIS LEANS
The combination of a PI-RADS 4 lesion and a rising PSA trajectory strongly suggests that further characterization via biopsy is warranted to assess the nature of the lesion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI, PSA trend, previous notes) strongly lean towards biopsy based on the PI-RADS 4 finding and rising PSA trajectory, settling the decision point for this round.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the rising PSA velocity (2.7 ng/mL/yr) and the specific PI-RADS 4 score, which are critical dynamic factors not fully captured by static variables like prior biopsy status or baseline PSA.
The prior did not weigh the specific PSA density (0.14 ng/mL²) or the DRE finding (Nodus), which are key components in risk stratification matrices referenced in the guidelines.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.41 +/- 0.17, placing it in the 'discuss' tier. Given the rising PSA (10.2 to 13.2 ng/mL) and PI-RADS 4, a low probability for biopsy might be dangerously conservative, especially if the underlying data distribution is skewed towards higher risk in this specific subgroup. The high aleatoric uncertainty (H=0.98) indicates the model is highly uncertain about the correct classification for this specific patient profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size and zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value of 13.2 ng/mL?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement regarding the prior positive biopsy?
4. laboratory panel - (Dropped by Moderator, but if retrieved, it might provide context on other markers).

GUIDELINE ANCHOR
The guideline search indicates that the decision is heavily dependent on the MRI findings and the prior biopsy status, noting that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15ng/mL/cc.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC \u2013 Radiology Division
Date: 10 Jan 2025 | Modality: Multiparametric MRI Prostate

Imaging Details: The gland demonstrates marked hypertrophy, totaling 96.0 mL in overall volume. Within the left mid-gland peripheral zone, a 12 x 8 mm focus exhibits restricted diffusion on DWI/ADC alongside early enhancement on DCE sequences. T2-weighted sequences reveal intermediate signal intensity; capsular integrity remains intact with no seminal vesicle involvement. Benign nodular hyperplasia diffusely expands the transition zone. Pelvic lymph nodes appear unremarkable.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 4 lesion in the left mid-gland peripheral zone with restricted diffusion and early enhancement.
- PSA trend: Serial PSA rise from 10.2 ng/mL (Mar 2024) to 13.2 ng/mL (Jan 2025), indicating a rising trajectory.

AGAINST Sampling this patient now:
- Previous notes: Prior biopsy result is documented as 'Positive', which is a known diagnosis.

WHERE THIS LEANS
The combination of a PI-RADS 4 lesion and a rising PSA trajectory strongly suggests that further characterization via biopsy is warranted to assess the nature of the lesion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI, PSA trend, previous notes) strongly lean towards biopsy based on the PI-RADS 4 finding and rising PSA trajectory, settling the decision point for this round, despite a disagreement between the statistical prior (No Biopsy) and the evidence (Biopsy).

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference split between deferral and biopsy, with the statistical prior suggesting no biopsy (p=0.41) and the evidence leaning towards biopsy due to the PI-RADS 4 finding and rising PSA trajectory. The evidence supported proceeding with biopsy because the retrieved MRI report showed a PI-RADS 4 lesion with restricted diffusion, which overturned the statistical prior's suggestion to defer. The guideline criterion abstained because the panel was insufficient, leaving the decision to the retrieved documents, which pointed toward further characterization.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
